RecruitingNCT06078553
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4
Studying Congenital myasthenic syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- argenx
- Enrollment
- 100 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2024 – 2027
Study locations (19)
- UC Davis Health - UC Davis Health Midtown Ambulatory Care Center, Sacramento, California, United States
- Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital, Chicago, Illinois, United States
- Hospital Sisters Health System (HSHS) - St Elizabeth's Hospital, O'Fallon, Illinois, United States
- Medical University of Vienna, Vienna, Austria
- The Ottawa Hospital - Civic Campus, Ottawa, Canada
- CHU Bordeaux - Groupe Hospitalier Pellegrin - Neurology, Bordeaux, France
- Hospices Civils de Lyon (HCL) - Hopital Pierre Wertheimer - Neurology, Bron, France
- CHU Lille Hopital Salengro - Neurology, Lille, France
- CHU Timone, Marseille, France
- Assistance Publique Hopitaux de Paris - Hopital Pitie-Salpetriere, Paris, France
- Universitaetsklinikum Essen (AoR), Essen, Germany
- Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
- National Hospital Organization Akita Hospital - Neurology, Yurihonjō, Japan
- Centrum Medyczne Neurologia Slaska - Neurology, Katowice, Poland
- Hospital Sant Joan de Deu - Pediatric Neurology, Esplugues de Llobregat, Spain
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06078553 on ClinicalTrials.govOther trials for Congenital myasthenic syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06630650A Prospective Natural History and Outcome Measure Validation Study of Congenital Myasthenic SyndromesNational Institute of Neurological Disorders and Stroke (NINDS)
- RECRUITINGPHASE1NCT07226726Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome SolutionThe Foundation for Orthopaedics and Regenerative Medicine
- RECRUITINGPHASE1NCT06436742A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)argenx